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Propensity score matched cumulative one year costs
Variable
EES BMS Difference p for
(N  714) (N  714) (95% CI) Difference
Index stenting
cost, $
2288 1104
[1,650]
1107528
[800]
1181
(1094 to 1274)
0.001
Follow-up costs
Repeat
revascularization
cost, $
917 7551
[0]
2086 9395
[0]
-1169
(-2105 to -344)
0.010
Clopidogrel
therapy cost, $
1939 562
[2139]
1496 862
[2139]
443
(367 to 511)
0.001
Aggregate 1-year
cost, $
5145 7612
[3789]
4689 9436
[2939]
456
(-508 to 1291)
0.32
Assuming
generic
clopidogrel cost,
$*
3537 7662
[2015]
3448 9429
[1165]
88
(-864 to 922)
0.85
Values in brackets are medians. *Cost of generic clopidogrel assumed as $1/day.
Conclusions: In this prospective observational registry, the cost per TLR avoided with
EES was $10,000. With the advent of generic thienopyridine availability, the cost
effectiveness profile shifts significantly in favor of EES, with similar 1-year aggregate
costs compared to BMS.
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Background: The efficacy and safety of XIENCE V® everolimus-eluting coro-
nary stents (XIENCE V, Abbott Vascular, Santa Clara, CA, USA) have been
demonstrated in pre-marketing and post-marketing studies with low rates of target
lesion revascularization (TLR), major cardiac adverse events and stent thrombosis
(ST). However, these results were mainly obtained in populations of European
heritage. SEEDS is the first study in China to evaluate XIENCE V’s performance
in Chinese patients with complex lesions.
Methods: This is a prospective, multicenter registry designed to enroll up to 1900
patients with long lesions or small vessel/multivessel coronary disease at 45 sites in
Mainland China, Taiwan and Macao. The primary endpoint is ischemia-driven target
vessel failure (TVF) at 12-month. Clinical follow-up is at 30 days, 6, 12 and 24 months.
All clinical endpoints are adjudicated by independent clinicians and 100% of data are
monitored. In this analysis, descriptive statistics are provided for baseline characteristics
and clinical endpoints by an independent statistical commission.
Results: A total of 365 (19.2%) small vessel patients, 781 (41.1%) long lesion patients,
and 754 (39.7%) multivessel patients with 2825 lesions were treated. Clinical, device and
lesion success rates were 99.47%, 99.95%, and 99.96% respectively. The table below
shows baseline characteristics and 30-day clinical outcomes.
Table: Baseline Characteristics and 30-Day Clinical Outcome
Baseline
Characteristics
(N1,900)
Age (years) 59.59 9.50
Diabetes 27.94%
Current smoker 42.42%
Hypertension 64.35%
Hyperlipidemia 37.33%
Prior MI 25.11%
% Pts with  2 Stents/Lesion 31.22%
Total stent length/lesion
(mm)
22.50 5.49
Clinical Endpoint Results at 30 Days
Small
Vessel
Long
Lesion
Multivessel
Disease All
(n365) (n781) (n754) (n1,900)
Death 0.00% 0.00% 0.27% 0.11%
Cardiac
death
0.00% 0.00% 0.27% 0.11%
MI 2.47% 2.56% 4.11% 3.16%
Q-wave MI 0.27% 0.38% 0.40% 0.37%
Non Q-wave
MI
2.19% 2.18% 3.71% 2.79%
TLR 0.0% 0.0% 0.27% 0.11%
TVF 2.47% 2.56% 4.77% 3.42%
Acute ST
(Def/Prob)
0.00% 0.26% 0.27% 0.21%
Subacute
ST(Def/
Prob)
0.55% 0.00% 0.40% 0.26%
Conclusions: In this large, multicenter, real-world study of Chinese population with
complex lesion subsets, XIENCE V demonstrated low rates of ST, TLR and TVF at
30-day. Long-term results will document the safety and effectiveness of XIENCE V in
high risk cohorts with long lesion and small vessel/multivessel disease from clinical
settings in China. 6-month results will be available at TCT Miami.
TCT-608
Two-Year Outcomes after Implantation of XIENCE PRIME and XIENCE
PRIME Long Lesion Stents in Patients with Coronary Artery Disease: Results
of the SPIRIT PRIME Multicenter Pivotal Clinical Trial
Marco Costa1, Dean Kereiakes2, Robert Smith3, Ken Wu3, Xiaohe Yu3,
Louis Cannon4, John Wang5, Krishnankutty Sudhir3
1Case Western Reserve University, Cleveland, USA, 2The Christ Hospital Heart &
Vascular Center, Cincinnati, USA, 3Abbott Vascular, Santa Clara, CA, 4McLaren
Northern Michigan Hospital, Heart & Vascular Institute, Petoskey, Michigan,
5Union Memorial Hospital, Baltimore, MD
Background: The SPIRIT PRIME trial demonstrated the clinical equivalence of the next
generation XIENCE PRIME everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) to the XIENCE V EES at 1 year. Longer-term outcomes with the XIENCE
PRIME stent have not been investigated.
Methods: SPIRIT PRIME, a prospective, pivotal, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME in both core size (CSR) and long length (LLR)
(33 and 38 mm) stent registries. The CSR analyzed 401 patients and the LLR 104 patients.
Treatment of up to 2 de novo lesions in different epicardial vessels was allowed. The
primary endpoint was 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data and in
accordance with FDA requirements. Data were fully monitored and all endpoint events
adjudicated by an independent clinical events committee.
Results: There were 447 target lesions treated in the CSR and 124 in the LLR. Clinical
device success rates were 98.2% in the CSR and 97.6% in the LLR. Female and diabetic
subjects were 29.7% and 34.9% in the CSR and 37.5% and 35.6%, in the LLR,
respectively. Elderly subjects (65 years old) comprised 41.6% of the CSR and 46.2% of
the LLR. The Table shows outcomes through 2 years.
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